How to Treat EGFR-Mutated Non-Small Cell Lung Cancer

被引：4
|
作者：
Belani, Neel [1 ,4 ]
Liang, Katherine [2 ]
Fradley, Michael [3 ]
Judd, Julia [1 ]
Borghaei, Hossein [1 ]
机构：
[1] Fox Chase Canc Ctr, Dept Hematol & Oncol, Philadelphia, PA USA
[2] Temple Univ Hlth Syst, Dept Internal Med, Philadelphia, PA USA
[3] Univ Penn, Perelman Sch Med, Cardiooncol Translat Ctr Excellence, Div Cardiol, Philadelphia, PA 19104 USA
[4] Univ Penn, Perelman Sch Med, 333 Cotman Ave, Philadelphia, PA 19111 USA
来源：
JACC: CARDIOONCOLOGY | 2023年 / 5卷 / 04期
关键词：
cardiomyopathy; lung cancer; tyrosine kinase inhibitor; OSIMERTINIB;
D O I：
10.1016/j.jaccao.2023.04.005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：542 / 545
页数：4
相关论文
共 50 条
  • [31] Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer
    Eltayeb, Kamal
    La Monica, Silvia
    Tiseo, Marcello
    Alfieri, Roberta
    Fumarola, Claudia
    CELLS, 2022, 11 (03)
  • [32] MERTK Activation Drives Osimertinib Resistance in EGFR-Mutated Non-Small Cell Lung Cancer
    Yan, D.
    Huelse, J.
    Parker, R.
    Wang, X.
    Frye, S.
    Earp, H. S.
    Deryckere, D.
    Graham, D.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : S1147 - S1147
  • [33] Upfront osimertinib in EGFR-mutated non-small cell lung cancer: is brain still a sanctuary?
    Leonetti, Alessandro
    Facchinetti, Francesco
    Tiseo, Marcello
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6
  • [34] Tumor PKCδ instigates immune exclusion in EGFR-mutated non-small cell lung cancer
    Zuo, Yi-Han
    Gao, Wei-Na
    Xie, Ya-Jia
    Yang, Sheng-Yong
    Zhou, Jin-Tai
    Liang, Hai-Hai
    Fan, Xing-Xing
    BMC MEDICINE, 2022, 20 (01)
  • [35] Stratifying Risk in Oligoprogressive EGFR-Mutated Non-Small Cell Lung Cancer: The Role of ctDNA
    Arrieta, O.
    Guijosa, A.
    Heredia, D.
    Davila-Dupont, D.
    Rios-Garcia, E.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S323 - S324
  • [36] Pharmacokinetics of edoxaban in EGFR-mutated non-small cell lung cancer patients with venous thromboembolism
    Hotta, Takamasa
    Tsubata, Yukari
    Hamai, Kosuke
    Tanino, Akari
    Kobayashi, Misato
    Nakamura, Atsushi
    Sugisaka, Jun
    Hongoh, Masafumi
    Ishihara, Noriyuki
    Ishikawa, Nobuhisa
    Yamasaki, Masahiro
    Fujitaka, Kazunori
    Kubota, Tetsuya
    Nishimura, Nobuhiro
    Isobe, Takeshi
    RESPIRATORY INVESTIGATION, 2021, 59 (03) : 327 - 334
  • [37] RNA Sequencing to Characterize Pathways in Patients with EGFR-mutated Non-Small Cell Lung Cancer
    Yun, N. K.
    Pope, C.
    Cagin, K. M.
    Naqib, A.
    Borgia, J. A.
    Fidler, M. J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S449 - S449
  • [38] Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
    Fu, Kai
    Xie, Fachao
    Wang, Fang
    Fu, Liwu
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
  • [39] Influence of Concurrent Mutations on Overall Survival in EGFR-mutated Non-small Cell Lung Cancer
    Chevallier, Mathieu
    Tsantoulis, Petros
    Addeo, Alfredo
    Friedlaender, Alex
    CANCER GENOMICS & PROTEOMICS, 2020, 17 (05) : 597 - 603
  • [40] Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated With Osimertinib
    Kunimasa, Kei
    Kamada, Risa
    Oka, Toru
    Oboshi, Makiko
    Kimura, Madoka
    Inoue, Takako
    Tamiya, Motohiro
    Nishikawa, Tatsuya
    Yasui, Taku
    Shioyama, Wataru
    Nishino, Kazumi
    Imamura, Fumio
    Kumagai, Toru
    Fujita, Masashi
    JACC: CARDIOONCOLOGY, 2020, 2 (01): : 1 - 10
12345